Related Experiment Video
Updated: Feb 10, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
Published on: April 9, 2014
Emerging reverse transcriptase inhibitors for HIV-1 infection.
Mohammad A Rai1, Sam Pannek1, Carl J Fichtenbaum1
1a Department of Internal Medicine , University of Cincinnati Medical Center , Cincinnati , OH , USA.
Newer antiretroviral therapies (ART) show promise for HIV treatment. Emerging drugs offer improved side effect profiles, better resistance management, and longer durations, potentially enhancing patient adherence and satisfaction.
Area of Science:
- Virology
- Pharmacology
- Infectious Diseases
Background:
- Antiretroviral therapy (ART) is crucial for managing HIV, with nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) forming its core.
- Existing NRTIs and non-nucleoside reverse transcriptase inhibitors (NNRTIs) face challenges including significant side effects and developing resistance.
- Over 36 million people live with HIV globally, highlighting the need for effective and well-tolerated treatments.
Purpose of the Study:
- To review resistance mechanisms and limitations of current NRTIs and NNRTIs.
- To evaluate promising new agents in the development pipeline for HIV treatment.
- To discuss the potential impact of novel reverse transcriptase inhibitors on ART.
Main Methods:
- Literature review focusing on resistance mechanisms of NRTIs and NNRTIs.
- Analysis of data on emerging HIV therapeutics, including GS-9131, MK-8591, Elsulfavirine, and Doravirine.
- Expert opinion synthesis on the future of ART development.
Main Results:
- Four new agents (GS-9131, MK-8591, Elsulfavirine, Doravirine) are in advanced development.
- MK-8591 offers potential for longer-acting formulations to improve adherence.
- Doravirine demonstrates efficacy against common mutations with fewer side effects and drug interactions.
Conclusions:
- Newer reverse transcriptase inhibitors possess longer half-lives and improved safety profiles.
- Emerging agents like Doravirine and Elsulfavirine show potential for enhanced efficacy and tolerability.
- Advancements in ART development offer improved options for patients living with HIV.
More Related Videos
Related Concept Videos
Emerging Adulthood
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Introduction Cardiac Emergencies
Reversible and Irreversible Processes
Diode: Reverse bias
Applications of GIS: Disaster Management and Emergency Response

